Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Levodopa strengths and weaknesses.

Joseph Jankovic1

  • 1Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, TX 77030, USA. josephj@bcm.tmc.edu

Neurology
|March 23, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychogenic (Functional) Movement Disorders.

Continuum (Minneapolis, Minn.)·2019
Same author

Juvenile parkinsonism: Differential diagnosis, genetics, and treatment.

Parkinsonism & related disorders·2019
Same author

Young-onset Parkinson's disease: Its unique features and their impact on quality of life.

Parkinsonism & related disorders·2019
Same author

Genetic Counseling in Huntington's Disease: Potential New Challenges on Horizon?

Frontiers in neurology·2019
Same author

Clinical phenotype in carriers of intermediate alleles in the huntingtin gene.

Journal of the neurological sciences·2019
Same author

Autosomal dominant mitochondrial membrane protein-associated neurodegeneration (MPAN).

Molecular genetics & genomic medicine·2019
Same journal

Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

Neurology·2026
Same journal

Cost-Effectiveness of Intracranial Aneurysm Screening: A Systematic Review.

Neurology·2026
Same journal

Rare Eating Epilepsy: Co-Occurrence of Focal Cortical Dysplasia and Gray Matter Heterotopia.

Neurology·2026
Same journal

Spatiotemporal Associations Between Cortical Microinfarcts and Cortical Superficial Siderosis in Cerebral Amyloid Angiopathy.

Neurology·2026
Same journal

Blood-Brain Barrier Disruption Before Interhospital Transfer for Thrombectomy and Clinical Outcome.

Neurology·2026
Same journal

At Death's Door: Cytosolic Dopamine in Patients With Parkinson Disease.

Neurology·2026
See all related articles

Levodopa is the most effective Parkinson's disease (PD) drug but causes motor complications. This review explores levodopa's side effects and strategies for managing them, addressing concerns about potential neurotoxicity.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Levodopa has been a cornerstone in Parkinson's disease (PD) treatment for over 30 years.
  • Despite its efficacy, levodopa is linked to significant motor complications like fluctuations and dyskinesias.
  • Concerns regarding potential levodopa-induced neurotoxicity persist, though in vivo studies do not support this.
  • The precise role and long-term effects of levodopa in PD management remain subjects of ongoing research and debate.

Purpose of the Study:

  • To critically review the mechanisms underlying levodopa-related complications in Parkinson's disease.
  • To discuss current therapeutic strategies for preventing and managing these motor complications.
  • To address the controversy surrounding potential levodopa neurotoxicity.

Main Methods:

Related Experiment Videos

  • Literature review of clinical experience and scientific studies on levodopa in Parkinson's disease.
  • Analysis of in vitro and in vivo research investigating levodopa's effects.
  • Synthesis of data on the incidence, mechanisms, and management of levodopa-induced motor complications.

    • Main Results:

    • Levodopa remains the most effective treatment for Parkinson's disease symptoms.
    • Motor complications, including fluctuations and dyskinesias, are common side effects associated with long-term levodopa use.
    • Current evidence does not support levodopa-induced neurotoxicity in vivo, despite some in vitro findings.

    Conclusions:

    • Levodopa's benefits in Parkinson's disease are significant, but managing its associated motor complications is crucial.
    • Further research is needed to fully elucidate the mechanisms of levodopa-induced complications and optimize treatment strategies.
    • Effective management strategies can mitigate levodopa-related side effects, improving patient quality of life.